RIPK4 and melanoma: In our prior study, we demonstrated heterogeneous expression of RIPK4 in melanoma samples, where it acts as an oncogene, in contrast to cutaneous squamous cell carcinoma, where it functions as a tumor suppressor (Madej et al. 2021).